专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06352844B1 Treatment of hyperproliferative disorders 有权
标题翻译：治疗过度增生性疾病
公开(公告)号：US06352844B1
公开(公告)日：2002-03-05
申请号：US09342019
申请日：1999-06-28
申请人： Barry J. Maurer , Myles Cabot , C. Patrick Reynolds
发明人： Barry J. Maurer , Myles Cabot , C. Patrick Reynolds
IPC分类号： C12N1509
CPC分类号： A61K45/06 , A61K31/07 , A61K31/165 , A61K31/535 , A61K31/70 , Y10S424/15 , A61K2300/00
摘要： A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-generating retinoid such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) at least one (and in certain embodiments at least two) ceramide degredation inhibitor, such as compounds selected from the group consisting of (i) glucosylceramide synthesis inhibitors, (ii) sphingosine-1-phosphate synthesis inhibitors, and (iii) protein kinase C inhibitors. A preferred glucosyl ceramide synthesis inhibitor is 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred sphingosine-1-phosphate synthesis inhibitor is D-erythro-N,N-dimethylsphingosine. A preferred protein kinase C inhibitor is L-threo-dihydrosphingosine.
摘要翻译：一种治疗需要这种治疗的受试者的过度增殖性疾病的方法，包括给所述受试者组合施用治疗有效量的：（a）产生神经酰胺的类视黄醇例如芬维A胺或其药学上可接受的盐; 和（b）至少一种（和在某些实施方案中至少两种）神经酰胺降解抑制剂，例如选自（i）葡糖基神经酰胺合成抑制剂，（ii）鞘氨醇-1-磷酸合成抑制剂和（iii））蛋白激酶C抑制剂。优选的葡糖基神经酰胺合成抑制剂是1-苯基-2-棕榈酰氨基-3-吗啉代-1-丙醇。优选的鞘氨醇-1-磷酸合成抑制剂是D-赤式-N，N-二甲基鞘氨醇。优选的蛋白激酶C抑制剂是L-苏式 - 二氢鞘氨醇。

2. 发明授权

US6090565A Sphingoglycolipids as markers for multidrug resistant cancers 失效
标题翻译：鞘氨醇作为多药耐药性癌症的标志物
公开(公告)号：US6090565A
公开(公告)日：2000-07-18
申请号：US964656
申请日：1997-11-05
申请人： Myles Cabot
发明人： Myles Cabot
IPC分类号： A61K31/138 , A61K31/277 , A61K38/13 , G01N33/574 , G01N33/92 , G01N33/567 , G01N33/48 , G01N33/53
CPC分类号： G01N33/92 , A61K31/138 , A61K31/277 , A61K38/13 , G01N33/574 , G01N2800/44 , Y10T436/25
摘要： The present invention involves the identification of sphingoglycolipid species that are indicative of multidrug resistance in certain types of cells, including cancer cells. The association of multidrug resistance with the expression of certain sphingoglycolipids provides a new method for identifying multidrug resistant cancers. In addition, it has been determined that reducing the levels of certain sphingoglycolipids results in enhanced chemosensitivity of drug resistant cancer cells. This offers the opportunity to develop new treatments for multidrug resistant cancers.
摘要翻译：本发明涉及鉴定在特定类型的细胞（包括癌细胞）中指示多药耐药性的鞘糖脂种类。多药耐药与某些鞘糖脂表达的关联提供了一种鉴定多重耐药性癌症的新方法。此外，已经确定降低某些鞘糖脂的水平导致耐药性癌细胞的增强的化学敏感性。这提供了开发多药耐药性癌症新疗法的机会。

3. 发明授权

US5885786A Methods for screening of substances for inhibition of multidrug resistance 失效
标题翻译：筛选抑制多药耐药物质的方法
公开(公告)号：US5885786A
公开(公告)日：1999-03-23
申请号：US636513
申请日：1996-04-19
申请人： Myles Cabot
发明人： Myles Cabot
IPC分类号： A61K31/138 , A61K31/277 , A61K38/13 , G01N33/574 , G01N33/92 , G01N33/53
CPC分类号： G01N33/92 , A61K31/138 , A61K31/277 , A61K38/13 , G01N33/574 , G01N2800/44 , Y10T436/25
摘要： The present invention provides for the screening of candidate substances to identify active compounds that inhibit multidrug resistance (MDR). The expression of glucosylceramides has been determined to be a marker of MDR. By measuring glucosylceramide expression in cells exhibiting MDR, and the reduction in glucosylceramide levels in the presence of a candidate substance, the present invention provides for the identification of MDR inhibitory compounds.
摘要翻译：本发明提供了候选物质的筛选以鉴定抑制多药耐药性（MDR）的活性化合物。葡萄糖神经酰胺的表达已被确定为MDR的标志物。通过测量显示MDR的细胞中的葡萄糖神经酰胺表达和在候选物质存在下葡糖基神经酰胺水平的降低，本发明提供了鉴定MDR抑制化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式